Cargando…
PD-L1 evaluation in the gastrointestinal tract: from biological rationale to its clinical application
Immune-checkpoint inhibitors targeting the PD-1/PD-L1 axis have brought significant clinical benefit in many solid cancer types, including gastrointestinal malignancies. However, it has been estimated that only 20-40% of patients respond to treatment. The pattern of expression and potential predicti...
Autores principales: | Mastracci, Luca, Grillo, Federica, Parente, Paola, Gullo, Irene, Campora, Michela, Angerilli, Valentina, Rossi, Chiara, Sacramento, Maria Luisa, Pennelli, Gianmaria, Vanoli, Alessandro, Fassan, Matteo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Pacini Editore srl
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614301/ https://www.ncbi.nlm.nih.gov/pubmed/36305021 http://dx.doi.org/10.32074/1591-951X-803 |
Ejemplares similares
-
A practical approach for PD-L1 evaluation in gastroesophageal cancer
por: Angerilli, Valentina, et al.
Publicado: (2022) -
Molecular Landscapes of Gastric Pre-Neoplastic and Pre-Invasive Lesions
por: Businello, Gianluca, et al.
Publicado: (2021) -
“Stranger things” in the gut: uncommon items in gastrointestinal specimens
por: Grillo, Federica, et al.
Publicado: (2021) -
Gut inflammation and tumorigenesis: every site has a different tale to tell
por: Vanoli, Alessandro, et al.
Publicado: (2023) -
Neuroendocrine neoplasms of the esophagus and stomach
por: Mastracci, Luca, et al.
Publicado: (2021)